Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2024-02-05 | 2024-02-05 |
| Drug Identification Number | 02469456 | 02469456 |
| Brand name | ETHACRYNATE SODIUM FOR INJECTION USP | ETHACRYNATE SODIUM FOR INJECTION USP |
| Common or Proper name | ETHACRYNATE SODIUM FOR INJECTION USP | ETHACRYNATE SODIUM FOR INJECTION USP |
| Company Name | STERIMAX INC | STERIMAX INC |
| Ingredients | ETHACRYNIC ACID | ETHACRYNIC ACID |
| Strength(s) | 50MG | 50MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1 VIAL | 1 VIAL |
| ATC code | C03CC | C03CC |
| ATC description | HIGH-CEILING DIURETICS | HIGH-CEILING DIURETICS |
| Reason for shortage | Shortage of an inactive ingredient or component. | Shortage of an inactive ingredient or component. |
| Anticipated start date | ||
| Actual start date | 2023-11-30 | 2023-11-30 |
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | VPI Ethacrynate Sodium is available at 75% allocation. | VPI Ethacrynate Sodium is available at 75% allocation. |
| Health Canada comments |